“The cautionary note is this all has to be confirmed in a larger trial,” says Douglas Ingram, Sarepta’s president and chief executive. “Our goal is to bring this therapy rapidly to patients around the world,” Ingram says.
Sarepta Gene Therapy Appears To Help Fourth Boy With Duchenne Muscular Dystrophy
